Skip to content
  • Clinical Studies
  • Pharma SOP’s
  • Pharma tips
  • Pharma Books
  • Stability Studies
  • Schedule M

Pharma GMP

Your Gateway to GMP Compliance and Pharmaceutical Excellence

  • Home
  • Quick Guide
  • GMP Failures & Pharma Compliance
    • Common GMP Failures
    • GMP Documentation & Records Failures
    • Cleaning & Sanitation Failures in GMP Audits
    • HVAC, Environmental Monitoring & Cross-Contamination Risks
  • Toggle search form

Status Label Design: Information, Format and Control Requirements

Posted on November 25, 2025November 25, 2025 By digi


Status Label Design: Information, Format and Control Requirements

Status Label Design: Information, Format, and Control Requirements

In pharmaceutical manufacturing, the implementation of a robust material status labelling system in GMP environments is fundamental for ensuring product quality, patient safety, and regulatory compliance. Effective status labelling provides clear communication on the acceptance, quarantine, or rejection status of raw materials, intermediates, packaging materials, and finished products throughout the supply chain and production lifecycle.

This step-by-step tutorial guide will cover the essential aspects of designing, formatting, and controlling status labels for materials in compliance with GMP. It targets professionals in pharmaceutical manufacturing, quality assurance (QA), quality control (QC), supply chain, and regulatory affairs within the US, UK, and EU jurisdictions under FDA, EMA, MHRA, PIC/S, and WHO GMP perspectives.

Step 1: Understand Regulatory and Good Manufacturing Practice Requirements for Material Status Labelling

The starting point for any material status labelling system in GMP is full understanding of relevant regulatory and GMP requirements. Labels are a critical element in controlling the materials used in pharmaceutical processes, facilitating traceability and preventing mix-ups and misuses.

Key regulations and guidance documents emphasize that all materials must be clearly identified by their status at every stage in the manufacturing and storage chain. For example:

  • FDA 21 CFR Part 211.101 requires all components, containers, and closures to be identified by a distinct label stating their status, such as “Quarantined,” “Rejected,” or “Released.”
  • The EU GMP Volume 4 Annex 15 on qualification and validation highlights the need to control materials via clear labelling to avoid errors in processing.
  • PIC/S PE 009-13 publication on Good Practices for Materials management provides detailed recommendations for effective labelling systems compliant with GMP standards.

Understanding these regulations ensures that label content and format meet the expectations of inspectors and auditors and protect product integrity.

Step 2: Define the Essential Label Content for Material Status Labels

Designing the label content is central to an effective status labelling system. Each label must convey all necessary information to clearly communicate a material’s current status without ambiguity.

The typical required elements on a material status label include:

  • Material Name and Description: Clear identification of the material, including any unique identifiers like catalog numbers or supplier codes.
  • Batch or Lot Number: Essential for traceability, this ensures materials are connected to documentation and testing records.
  • Status Designation: This is the most prominent part of the label and includes standard statuses such as “Quarantined,” “Released,” “Rejected,” “Hold,” or “Returned.”
  • Date of Label Issuance: The date when the status was assigned.
  • Responsible Person or Department: Identification of the individual or group authorizing the status, often accompanied by a signature or electronic authorization reference.
  • Instructions for Use or Handling: Any critical remarks to guide further processing, storage, or disposal.
  • Barcode or RFID (if applicable): For inventory management systems to electronically track materials.
Also Read:  How to Validate Blending Uniformity in Solid Dosage Manufacturing

The use of clear, standardized terminology is crucial. Avoid ambiguous or uncommon phrases that might cause confusion. For example, “Quarantined” must always mean a material not yet released for use pending evaluation.

Step 3: Specify the Format and Physical Design of Status Labels

Having determined the essential content, the next step focuses on format and physical design of the labels to ensure both durability and visibility across different environmental conditions found in warehouses, production lines, and laboratories.

Important considerations for label design include:

  • Size and Shape: The label should be large enough to display all required information legibly, yet appropriately sized to fit on containers of varying dimensions.
  • Material and Print Quality: Use high-quality label stock that resists smudging, tearing, and exposure to humidity, chemicals, or temperature extremes. Materials such as polyester, vinyl, or polypropylene are often preferred in GMP environments.
  • Color Coding: The use of standardized colors improves rapid identification. Typical conventions include red for “Rejected,” yellow or orange for “Quarantine,” green for “Released,” and blue or grey for “On Hold.” These color codes must be consistently applied across the facility and documented in SOPs.
  • Font and Legibility: Fonts must be clear, typically sans-serif, with sufficient font size to be read easily under all lighting conditions. Contrast between text and background should be maximized.
  • Space for Handwritten Entries or Signatures: If part of the issuance process requires handwritten input, clearly allocated fields must exist on the label.
  • Attachment Method: Labels should be affixed with GMP-compliant adhesives or mechanical holders to prevent unintentional removal or loss.

The control of label format is critical; any deviation or use of unofficial labels can cause serious quality risks and regulatory findings during inspections.

Also Read:  Audit Observations on Weak Stock Verification and Inventory Control

Step 4: Establish Stringent Control and Issuance Procedures for Status Labels

Beyond design, controlling the use, issuance, and replacement of status labels is fundamental. The control element ensures that labels serve their function as part of an auditable GMP system.

Key elements of control and issuance include:

  • Approval and Change Control: All label designs and formats must be formally approved by QA and documented. Any changes are subject to revision control and documented through change control procedures, per regulatory guidance such as EU GMP Annex 15.
  • Restricted Access: Physical inventory of blank status labels should be tightly controlled and stored securely to prevent unauthorized use. Access should be logged and limited to trained personnel.
  • Issuance Procedures: Labels should only be issued following a documented procedure specifying the conditions under which particular statuses are assigned. This procedure must ensure labels are issued with correct information, including date and approver.
  • Label Lifecycle Management: Controls must address removal and replacement of labels when a material status changes, as well as proper disposal of obsolete labels to prevent reuse or confusion.
  • Training and Awareness: Personnel involved in labelling must be trained on the significance of each label status, how to issue and apply labels correctly, and the associated risks of misuse.
  • Regular Review and Audits: Routine internal audits should verify that label usage aligns with SOPs and regulatory expectations, identifying control gaps promptly.

Implementing electronic systems such as barcode scanning linked to the manufacturing execution system (MES) can improve control and traceability of status labelling further, while reducing human error.

Step 5: Integrate Status Labelling System within Overall Material Management Workflow

A compliant and secure material status labelling system in GMP cannot operate in isolation. It must be integrated seamlessly with procurement, receipt, storage, sampling, testing, release, and distribution workflows to ensure continuous material control.

Best practices for integration include:

  • Process Mapping: Map each stage within the material management lifecycle where status labeling applies, from initial receipt through to finished product disposition.
  • Documentation Alignment: Link labels to corresponding batch records, material master data, certificates of analysis (CoA), and computerized inventory systems.
  • Automated Status Updates: Where possible, update material status electronically based on testing results or QA review, triggering issuance of corresponding physical labels.
  • Visual Management: Use appropriate label placement to support visual management techniques, helping operators quickly identify material status without consulting electronic systems.
  • Change Management: When materials are reworked, returned, recalled, or dispositioned, label status must be updated promptly to reflect current conditions.
Also Read:  Material Status Labelling System in GMP Warehouses: Design and Control

This comprehensive approach reduces errors such as accidental use of rejected materials or delays in processing quarantined stock, highly valued by regulatory bodies during GMP inspections and audits.

Step 6: Monitor, Review, and Continuously Improve the Status Labelling System

Pharmaceutical companies must establish mechanisms for ongoing monitoring and review of the material status labelling system in GMP environments to maintain compliance and enhance effectiveness.

Actions for continuous improvement include:

  • Incident and Deviation Analysis: Investigate any label-related deviations, such as use of mislabeled materials, to identify root causes and implement corrective actions.
  • Periodic Label Effectiveness Review: Conduct scheduled reviews of label formats, durability, readability, and application to ensure they continue to meet operational needs and regulatory standards.
  • Audit Findings Remediation: Address any non-conformities identified in regulatory or internal audits related to labeling controls promptly and systematically.
  • User Feedback: Engage warehouse, manufacturing, QC, and QA personnel regularly to collect feedback on label usability and visibility to inform improvements.
  • Technology Upgrades: Assess opportunities to automate labelling or incorporate new methods like smart labels or RFID for enhanced control and data capture aligned with ICH Q10 Pharmaceutical Quality System principles.

Commitment to continuous monitoring and upgrading of the material status labelling system helps ensure long-term GMP compliance and minimizes risk of product quality incidents linked to material misidentification.

Summary and Key Takeaways

An effective material status labelling system in GMP is essential to pharmaceutical quality and compliance. The step-by-step approach comprises:

  • Understanding relevant regulatory and GMP requirements related to labelling control.
  • Defining standardized label content including status, batch numbers, responsible personnel, and instructions.
  • Designing durable, legible, and standardized label formats with appropriate color coding and physical materials.
  • Implementing strict controls over label issuance, storage, approval, and replacement procedures.
  • Integrating labels with the overall material management workflows to ensure accuracy and traceability.
  • Establishing monitoring, review, and continuous improvement mechanisms to sustain system integrity and compliance.

Pharmaceutical companies applying these principles will strengthen their control over material flows, thereby reducing the risks of contamination, mix-ups, and regulatory deviations. For more detailed guidance, consulting original regulatory texts such as the FDA’s current Good Manufacturing Practice regulations and EMA’s GMP Annexes is highly recommended.

Status Labelling Tags:content, control, design, pharmagmp, status labels

Post navigation

Previous Post: Checklist for Raw Material Receipt and Documentation in Warehouses
Next Post: Avoiding Mix-Ups Through Effective Status Labelling in Warehouses

Quick Guide

  • GMP Basics
    • Introduction to GMP
    • What is cGMP?
    • Key Principles of GMP
    • Benefits of GMP in Pharmaceuticals
    • GMP vs. GxP (Good Practices)
  • Regulatory Agencies & Guidelines
    • WHO GMP Guidelines
    • FDA GMP Guidelines
    • MHRA GMP Guidelines
    • SCHEDULE – M – Revised
    • TGA GMP Guidelines
    • Health Canada GMP Regulations
    • NMPA GMP Guidelines
    • PMDA GMP Guidelines
    • EMA GMP Guidelines
  • GMP Compliance & Audits
    • How to Achieve GMP Certification
    • GMP Auditing Process
    • Preparing for GMP Inspections
    • Common GMP Violations
    • Role of Quality Assurance
  • Quality Management Systems (QMS)
    • Building a Pharmaceutical QMS
    • Implementing QMS in Pharma Manufacturing
    • CAPA (Corrective and Preventive Actions) for GMP
    • QMS Software for Pharma
    • Importance of Documentation in QMS
    • Integrating GMP with QMS
  • Pharmaceutical Manufacturing
    • GMP in Drug Manufacturing
    • GMP for Biopharmaceuticals
    • GMP for Sterile Products
    • GMP for Packaging and Labeling
    • Equipment and Facility Requirements under GMP
    • Validation and Qualification Processes in GMP
  • GMP Best Practices
    • Total Quality Management (TQM) in GMP
    • Continuous Improvement in GMP
    • Preventing Cross-Contamination in Pharma
    • GMP in Supply Chain Management
    • Lean Manufacturing and GMP
    • Risk Management in GMP
  • Regulatory Compliance in Different Regions
    • GMP in North America (FDA, Health Canada)
    • GMP in Europe (EMA, MHRA)
    • GMP in Asia (PMDA, NMPA, KFDA)
    • GMP in Emerging Markets (GCC, Latin America, Africa)
    • GMP in India
  • GMP for Small & Medium Pharma Companies
    • Implementing GMP in Small Pharma Businesses
    • Challenges in GMP Compliance for SMEs
    • Cost-effective GMP Compliance Solutions for Small Pharma Companies
  • GMP in Clinical Trials
    • GMP Compliance for Clinical Trials
    • Role of GMP in Drug Development
    • GMP for Investigational Medicinal Products (IMPs)
  • International GMP Inspection Standards and Harmonization
    • Global GMP Inspection Frameworks
    • WHO Prequalification and Inspection Systems
    • US FDA GMP Inspection Programs
    • EMA and EU GMP Inspection Practices
    • PIC/S Role in Harmonized Inspections
    • Country-Specific Inspection Standards (e.g., UK MHRA, US FDA, TGA)
  • GMP Blog

Latest Posts

  • GMP-cGMP Regulations & Global Standards
    • FDA cGMP Regulations for Drugs & Biologics
    • cGMP Requirements for Pharmaceutical Manufacturers
    • ICH Q7 and API GMP Expectations
    • Global & ISO-Based GMP Standards
    • GMP for Medical Devices & Combination Products
    • GMP for Pharmacies & Hospital Pharmacy Settings
  • Applied GMP in Pharma Manufacturing & Operations
    • GMP for Pharmaceutical Drug Product Manufacturing
    • GMP for Biotech & Biologics Manufacturing
    • GMP Documentation
    • GMP Compliance
    • GMP for APIs & Bulk Drugs
    • GMP Training
  • Computer System Validation (CSV) & GxP Computerized Systems
    • CSV Fundamentals in Pharma & Biotech
    • FDA CSV Guidance & 21 CFR Part 11 Alignment
    • GAMP 5 & Risk-Based Validation Approaches
    • CSV in Pharmaceutical & GxP Industries (Use-Cases & System Types)
    • CSV Documentation
    • CSV for Regulated Equipment & Embedded Systems
  • Data Integrity & 21 CFR Part 11 Compliance
    • Data Integrity Principles in cGMP Environments
    • FDA Data Integrity Guidance & Expectations
    • 21 CFR Part 11 – Electronic Records & Signatures
    • Data Integrity in GxP Computerized Systems
    • Data Integrity Audits
  • Pharma GMP & Good Manufacturing Practice
    • FDA 483, Warning Letters & GMP Inspections
    • Data Integrity, ALCOA+ & Part 11 / Annex 11
    • Process Validation, CPV & Cleaning Validation
    • Contamination Control & Annex 1
    • PQS / QMS / Deviations / CAPA / OOS–OOT
    • Documentation, Batch Records & GDP
    • Sterility, Microbiology & Utilities
    • CSV, GAMP 5 & Automation
    • Dosage-Form–Specific GMP (Solids, Liquids, Sterile, Topicals)
    • Supply Chain, Warehousing, Cold Chain & GDP
Widget Image
  • Never Assign Batch Release Responsibilities to Non-QA Personnel in GMP

    Never Assign Batch Release Responsibilities… Read more

  • Manufacturing & Batch Control
    • GMP manufacturing process control
    • Batch Manufacturing record requirements
    • Master Batch record template for pharmaceuticals
    • In Process control checks in tablet manufacturing
    • Line clearance procedure before batch start
    • Batch reconciliation in pharmaceutical manufacturing
    • Yield reconciliation GMP guidelines
    • Segregation of different strength products GMP
    • GMP controls for high potency products
    • Cross Contamination prevention in manufacturing
    • Line clearance checklist for production
    • Batch documentation review before qa release
    • Process parameters control limits in pharma
    • Equipment changeover procedure GMP
    • Batch manufacturing deviation handling
    • GMP expectations for batch release
    • In Process sampling plan for tablets
    • Visual inspection of dosage forms GMP requirements
    • In Process checks for filled vials
    • Startup and Shutdown procedure for manufacturing line
    • GMP requirements for blending and mixing operations
    • Process Control strategy in pharmaceutical manufacturing
    • Uniformity of dosage units in process controls
    • GMP checklist for oral solid dosage manufacturing
    • Process Control
    • Batch Documentation
    • Master Batch Records
    • In-Process Controls
    • Line Clearance
    • Yield & Reconciliation
    • Segregation & Mix-Ups
    • High Potency Products
    • Cross Contamination Control
    • Line Clearance
    • Batch Review
    • Process Parameters
    • Equipment Changeover
    • Deviations
    • Batch Release
    • In-Process Sampling
    • Visual Inspection
    • In-Process Checks for Vials
    • Start-Up & Shutdown
    • Blending & Mixing
    • Control Strategy
    • Dosage Uniformity
    • Hold Time Studies
    • OSD GMP Checklist
  • Cleaning & Contamination Control
  • Warehouse & Material Handling
    • Warehouse GMP
    • Material Receipt
    • Sampling
    • Status Labelling
    • Storage Conditions
    • Rejected & Returned
    • Reconciliation
    • Controlled Drugs
    • Dispensing
    • FIFO & FEFO
    • Cold Chain
    • Segregation
    • Pest Control
    • Env Monitoring
    • Palletization
    • Damaged Containers
    • Stock Verification
    • Sampling & Weighing Areas
    • Issue to Production
    • Traceability
    • Printed Materials
    • Intermediates
    • Cleaning & Housekeeping
    • Status Tags
    • Warehouse Audit
  • QC Laboratory & Testing
    • Analytical Method Validation
    • Chromatography Systems
    • Dissolution Testing
    • Assay & CU
    • Impurity Profiling
    • Stability & QC
    • OOS Investigations
    • OOT Trending
    • Sample Management
    • Reference Standards
    • Equipment Calibration
    • Instrument Qualification
    • LIMS & Electronic Data
    • Data Integrity
    • Microbiology QC
    • Sterility & Endotoxin
    • Environmental Monitoring
    • QC Documentation
    • Results Review
    • Method Transfer
    • Forced Degradation
    • Compendial Methods
    • Cleaning Verification
    • QC Deviations & CAPA
    • QC Lab Audits
  • Manufacturing & In-Process Control
    • Batch Manufacturing Records
    • Batch Manufacturing Records
    • Line Clearance
    • In-Process Sampling & Testing
    • Yield & Reconciliation
    • Granulation Controls
    • Blending & Mixing
    • Tablet Compression Controls
    • Capsule Filling Controls
    • Coating Process Controls
    • Sterile & Aseptic Processing
    • Filtration & Sterile Filtration
    • Visual Inspection of Parenteral
    • Packaging & Labelling Controls
    • Rework & Reprocessing
    • Hold Time for Bulk & Intermediates
    • Manufacturing Deviations & CAPA
  • Documentation, Training & QMS
    • SOP & Documentation Control
    • Training & Competency Management
    • Change Control & QMS Lifecycle
    • Internal Audits & Self-Inspection
    • Quality Metrics, Risk & Management Review
  • Production SOPs
  • QC Laboratory SOPs
    • Sample Management
    • Analytical Methods
    • HPLC & Chromatography
    • OOS & OOT
    • Data Integrity
    • Documentation
    • Equipment
  • Warehouse & Materials SOPs
    • Material Receipt
    • Sampling
    • Storage
    • Dispensing
    • Rejected & Returned
    • Cold Chain
    • Stock Control
    • Printed Materials
    • Pest & Housekeeping
  • Cleaning & Sanitization SOPs
  • Equipment & Qualification SOPs
  • Documentation & Data Integrity SOPs
  • Deviation/OOS/CAPA SOPs
    • Deviation Management
    • Root Cause
    • CAPA
    • OOS/OOT
    • Complaints
    • Recall
  • Training & Competency SOPs
    • Training System
    • Role-Based Training
    • OJT
    • Refresher Training
    • Competency
  • QA & QMS Governance SOPs
    • Quality Manual
    • Management Review
    • Internal Audit
    • Risk Management
    • Vendors & Outsourcing
  • About Us
  • Privacy Policy & Disclaimer
  • Contact Us

Copyright © 2025 Pharma GMP.

Powered by PressBook WordPress theme